Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as balapiravir [RO4588161]
balapiravir · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| balapiravir [RO4588161] | DRUG | sequential cohorts receiving doses orally twice daily for 5 days |
| placebo | DRUG | orally twice daily for 5 days |
Inclusion Criteria: * male patients, 18-65 years of age * dengue virus infection (confirmed by NS1 strip test) with symptom onset \</=48 hours before first study drug administration * patients and their partners of childbearing potential must use 2 forms of contraception until 3 months after receiv...
Top 2 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Qdenga |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
Balapiravir is an investigational small molecule antiviral developed by Roche Holding AG for dengue virus infection. It has been studied in a single Phase 1 clinical trial conducted in Vietnam. Balapiravir is not an approved medicine and remains in clinical development.
Balapiravir was studied for the treatment of dengue virus infection. The only recorded clinical trial of balapiravir enrolled 64 adult male patients with dengue in Vietnam. Because balapiravir is investigational, it is not an approved treatment for dengue or any other condition.
Balapiravir is developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche sponsored the clinical research of balapiravir in dengue virus infection.
Balapiravir is in Phase 1 development. The single registered trial, NCT01096576, was a Phase 1 study in patients with dengue virus infection. That trial is completed, and no active trials of balapiravir are currently listed.
Balapiravir has been evaluated in one clinical trial, NCT01096576, titled A Study of Balapiravir in Patients With Dengue Virus Infection. It was a Phase 1, placebo-controlled, double-blind study that enrolled 64 adult male patients in Vietnam and is now completed.
Yes, balapiravir is also known as RO4588161, which is Roche's internal compound designation for the same investigational dengue antiviral. Both names refer to the identical small molecule drug candidate developed by Roche Holding AG.